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Abstract 
Background: Understanding the mechanisms of long chain fatty acid (LCFA) uptake in he-
patic cells is of high medical importance to treat and to prevent fatty liver disease (FLD). ACSs 
(Acyl-CoA synthetases) are a family of enzymes that catalyze the esterification of fatty acids 
(FA) with CoA. Recent studies suggest that ACS enzymes drive the uptake of LCFA indirectly 
by their enzymatic activity and could promote special metabolic pathways dependent on their 
localization. 
The only protein located at the plasma membrane which has consistently been shown to 
enhance FA uptake is CD36.  
Aims: The current study investigated whether ACSs and CD36 could regulate hepatic LCFA 
uptake. 
Methods and Results: FATP2 and FATP4 were both localized to the ER of HuH7 and 
HepG2 cells as shown by double immunofluorescence in comparison to marker proteins. 
ACSL1 was located at mitochondria in both cell lines. Overexpression of FATP2, FATP4 and 
ACSL1 highly increased ACS activity as well as the uptake of [3H]-oleic acid and fluorescent 
Bodipy-C12 (B12) fatty acid. Quantitative FACS analysis showed a correlation between ACS 
expression levels and B12 uptake. FATP2 had the highest effect on B12 uptake of all proteins 
tested. CD36 was mainly localized at the plasma membrane. Whereas [3H]-oleic acid uptake 
was increased after overexpression, CD36 had no effect on B12 uptake.  
Conclusion: Uptake of LCFA into hepatoma cells can be regulated by the expression levels 
of intracellular enzymes. We propose that ACS enzymes drive FA uptake indirectly by es-
terification. Therefore these molecules are potential targets for treatment of nonalcoholic 
fatty liver disease (NAFLD) or steatohepatitis (NASH). 
Key words: fatty acid transport, acyl-CoA synthetases, nonalcoholic fatty liver disease, nonalco-
holic steatohepatitis, CD36 
INTRODUCTION 
The  molecular  mechanism  of  long  chain  fatty 
acid (LCFA) uptake is still a matter of debate (for re-
views  see  [1-8]).  Understanding  this  process  is  im-
portant to elucidate potential targets for the treatment 
of lipid disorders like nonalcoholic fatty liver disease 
(NAFLD), which is caused by an accumulation of tri-
glycerides in the liver. A common feature for the he-
patic triglyceride accumulation is an elevated plasma 
level of free fatty acids (FFA) found especially in cor-
relation  with  obesity  and  insulin  resistance  [9,  10]. 
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Studies suggest that the rate of hepatic FFA uptake is 
directly  proportional  to  plasma  FFA  concentrations 
[11]. Obesity results in a marked enlargement of the 
intraabdominal visceral fat. The development of insu-
lin resistance leads to an elevated rate of lipolysis of 
these depots. Released LCFAs are transported to the 
liver where they are translocated across the plasma 
membrane, reassembled to triglycerides and stored in 
lipid  droplets  [12].  To  interfere  with  the  uptake 
mechanism is therefore a promising target for further 
therapeutic intervention for one of the major burdens 
of our society. The prevalence of hepatic steatosis in 
the general population is already estimated between 
14  %  and  24  %  with  an  increasing  tendency  in  all 
segments of the population [13, 14].  
The first step of LCFA uptake is its translocation 
across the plasma membrane. There is a high degree 
of  controversy  regarding  the  mechanism  of  LCFA 
translocation.  However,  the  concept  of  a  facilitated 
uptake  by  special  membrane  components  like  pro-
teins  and  lipid  rafts  had  become  popular  in  recent 
years  [1,  3,  8].  There  have  been  different  candidate 
proteins  published  that  are  possibly  involved  in 
LCFA  uptake  of  which  only  CD36  has  consistently 
been shown to be expressed at the plasma membrane 
and to enhance LCFA uptake upon overexpression [4]. 
CD36 is a scavenger protein that besides FAs can bind 
a variety of molecules including acetylated LDL, col-
lagen  and  phospholipids  [4,  15-18].  It  is  located  in 
lipid rafts and non-raft domains of the cellular plasma 
membrane and most likely facilitates LCFA transport 
by accumulating LCFA on the outer surface [3, 19, 20]. 
As CD36 has been shown to be expressed in liver tis-
sue [21, 22] as well and is upregulated in nonalcoholic 
fatty  liver  disease  (NAFLD)  [23]  and  nonalcoholic 
steatohepatitis (NASH) [22], we examined its capabil-
ity for LCFA uptake in our systems.  
The first step for intracellular use of LCFA is its 
esterification with coenzyme A (CoA). This reaction is 
catalyzed by acyl-CoA synthetases (ACSs). The pro-
duced  acyl-CoAs  are  substrates  for  ß-oxidation,  the 
synthesis of triacylglycerol, phospholipids, cholester-
ol esters as well as ceramides and are also a primary 
source of signaling molecules [2, 24]. In humans two 
related protein families for long chain fatty acid acti-
vation exist: The fatty acid transport proteins (FATPs) 
and the long chain acyl-CoA synthetases (ACSLs) [25, 
26]. They differ in tissue expression and in the cellular 
localization. Thereby they likely play a role in chan-
neling  LCFA  to  different  intracellular  metabolic 
pathways  [2,  27].  As  the  overexpression  of  most  of 
these proteins leads to an enhanced LCFA uptake [19, 
28-30], these enzymes are potential pharmacological 
targets. In this study we investigated ACSL1, FATP2 
and FATP4, all proteins that have been shown to be 
expressed in human liver [22, 23, 31-35]. 
We set the goal to better understand the role of 
FATP2,  FATP4,  ACSL1  and  CD36  in  LCFA  uptake 
and lipid metabolism of hepatocytes to point out po-
tential targets for treatment of hepatic steatosis.  
MATERIALS AND METHODS 
Reagents and Antibodies 
Antibodies used were mouse anti-placenta alka-
line phosphatase (PLAP) (Dako Cytomation), mouse 
anti-FLAG (Sigma), mouse anti-HA (Santa Cruz), Al-
lophycocyanin  (APC),  Cy2  and  Cy3  donkey  an-
ti-mouse (Jackson Immuno Research). 
Constructs 
GFP-FATP4  and  FATP4-FLAGhave  been  de-
scribed previously [29]. CD36-FLAG was kindly pro-
vided by Douglas M. Lublin, Washington University 
School  of  Medicine,  St.  Louis,  MO.  FLAG 
epitope-tagged ACSL1 [36] was a gift from Rosalind 
Coleman, PLAP cDNA [37] and HA epitope-tagged 
FATP2 were from our laboratory. 
Plasmid constructs used for localization studies 
were pOCT-GFP [38], a gift from Heidi McBride and 
mito-RFP (containing the N terminus of rat aldehyde 
dehydrogenase fused to mRFP) as markers for mito-
chondria. ADRP-mRFP1, a marker for lipid droplets, 
mRFP-sec61ß, a marker for ER and peroxisomal-RFP, 
a  marker  for  peroxisomes  were  gifts  of  Christoph 
Thiele and Lars Kürschner, MPI Molecular Cell Biol-
ogy,  Dresden,  Germany.  From  our  laboratory 
ssGFPglycTMDpcx as well as PLAP, both constructs 
for plasmamembrane marking, were used. 
Oleate Uptake 
Cumulative  uptake  of  oleate  was  based  on 
Stremmel  and  Berk  1986  [39].  Adherent  cells  were 
incubated for 5 min at 37 °C with [3H]oleate uptake 
solution  (170  µM  [3H]  oleate,  170  µM  BSA  in  PBS; 
specific  activity  4.1  Ci/mol).  After  stopping  and 
washing with ice-cold 0.5 % BSA in PBS, cells were 
lysed with 1 M NaOH and aliquots analyzed by scin-
tillation  counting  (Biorad)  for  protein  concentration 
and radioactivity as before [40]. 
Cells and transient transfection 
HuH7 (JCRB 0403) and HepG2 (ATCC HB-8065) 
cells were maintained under standard tissue culture 
conditions  with  the  appropriate  culture  media 
(HuH7: D-MEM Invitrogen; 4,5 g glucose/L, 10% FBS, 
2 mM L-Glutamine and HepG2: D-MEM Invitrogen; 
4,5 g glucose/L 10% FBS 2mM L-Glutamine, 1% So-Int. J. Med. Sci. 2011, 8 
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dium  pyruvate  Sigma,  1%  non-essential  aminoacid 
solution Sigma). HepG2 cells were grown on a Colla-
gen  R  surface  coating  (Serva).  Cells  grown  to  near 
confluency (10 cm²) were transfected with 2 μg plas-
mid-DNA and 10 μl FuGENE HD (Roche). Analysis 
was performed 24-48 hours after transfection.  
Immunofluorescence and confocal analysis 
For immunofluorescence microscopy, cells were 
fixed for 10 min with 4% PFA at RT followed by a 
permeabilisation  with  0.1%  saponin  (Sigma)  for  10 
min. Fixed cells were incubated for 1 hour at room 
temperature  with  the  appropriate  dilution  of  anti-
bodies in phosphate-buffered saline (PBS) containing 
0.2% gelatine and 0.1% saponin. 
After three washes with PBS/ 0.2% gelatine cells 
were incubated with the respective fluorescently la-
belled secondary antibodies in PBS containing 0.2% 
gelatine and 0.1% saponin for 1 hour at room tem-
perature. The antibody against PLAP and the anti-HA 
antibody were diluted 1:100, the anti-FLAG antibody 
1:1000.  
Cy3-labelled secondary antibodies were diluted 
1:1000, and the Cy2-labelled ones 1:200. The cells were 
fixed as described above. Coverslips were mounted in 
Mowiol and fluorescent images were acquired on a 
Leica  TCS  SP2  confocal  microscope  as  described  in 
[41] and arranged with Adobe Photoshop. All confo-
cal images are representative single sections. 
B12-FA uptake and FACS analysis 
Flow  cytometric  analyses  were  essentially  per-
formed  as  described  before  [29].  Transfected  HuH7 
and HepG2 cells were incubated with 2 µM B12-FA 
[Bodipy 3823 (4.4-difluoro-5.7-diphenyl-4-bora-3a,4a- 
diaza-s-indacene-3-dodecanoic-acid)  Invitrogen]  bo-
vine serum albumin (BSA) solution for 2 min. After 
the termination of FA uptake by adding ice-cold 0.1% 
BSA in PBS, the cells were trypsinized, fixed in sus-
pension with 4% paraformaldehyde and stained with 
the  appropriate  antibodies.  For  FATP2-HA, 
CD36-FLAG and ACSL1-FLAG staining we incubated 
the cells with APC (Allophycocyanin) as second an-
tibody  for  30  min.  FATP4  was  used  as  an 
RFP-construct.  Appropriate  controls  (for  autofluo-
rescence, single signals) were used for calibration of 
the FACS analysis. Cells were analyzed with a FACS 
Scan  and  LSRII  FACS  (BD  Biosciences).  Data  were 
exported  from  the  CellQuestPro  software  (BD  Bio-
sciences, San Jose, CA) and FACS Diva Software (BD 
Biosciences, San Jose, CA) and analyzed by spread-
sheet  calculations  [42].Moreover,  S(Bodipy)  [AU]  was 
calculated using the absolute number of cells overex-
pressing one of the candidate proteins (in % of all cells 
gated) and the overall mean of Bodipy fatty acid flu-
orescence measured. 
Acyl-CoA synthetase activity 
The protocol is based on  Hall et al.  [43]. Cells 
were lysed for 30 min on ice with 1% TX-100, 130 mM 
KCl,  25  mM  Tris-HCl,  pH  7.4.  Protein  lysates  were 
incubated for 10 min at 30°C in 100 mM Tris, pH 7.4, 5 
mM MgCl2, 200 µM dithiothreitol (DTT), 10 mM ATP, 
0.2%  TX-100,  20  µM  [3H]oleate  (specific  activity  10 
Ci/mol), 200 µM CoA. The reaction was stopped with 
Dole’s  solution  (isopropanol:  n-heptane:  H2SO4 
40:10:1),  unreacted  oleate  was  extracted  four  times 
with n-heptane and the remaining oleoyl-CoA in the 
aqueous phase determined by scintillation counting.  
Real time PCR 
First  cDNA  was  prepared  using  Transcriptor 
First Strand cDNA Synthesis Kit (Roche) and mRNA 
prepared using High Pure RNA Isolation Kit (Roche) 
according to the manufacturer´s instructions. The fi-
nal  RNA  concentrations  were  determined  spectro-
photometrically with BioPhotometer (Eppendorf).  
Using  reverse  transcription  quantitative  PCR 
(qPCR) we studied FATP2, FATP4, ACSL1 and CD36 
and obtained these to our housekeeping gene ß-Actin. 
For each gene investigated specific primers were 
designed  for  optimal  performance  with  its  specific 
annealing  temperature  by  software 
(http://frodo.wi.mit.edu/primer3/)  [44].  Primer 
pairs (self-designed) are listed below: 
ratACSL1 
Forward 
5’-TGGGCACAGAAGAGAGGATT-3’MT(°C): 63,8 
Reverse  
5’- ATGGCTTCAAACCAGCATTC-3’MT(°C): 63,9 
hACSL1 
Forward 
5’-CTTCTGGTACGCCACGAGAC-3’MT(°C): 64,8 
Reverse 
5’-GTCGCTGTCAAGTAGTGCG-3’MT(°C): 62,3 
hCD36 
Forward 
5’-TTGATGTGCAAAATCCACAGG-3’MT(°C): 65,7 
Reverse 
5’-TGTGTTGTCCTCAGCGTCCT-3’MT(°C): 66 
mFATP2 
Forward 
5’-TCGTGGGACTGGTAGATTTTG-3’MT(°C): 64 
Reverse 
5’-CGCGATGTGTTGAAAGAGTTT-3’MT(°C): 63,8 
hFATP2 
Forward 
5’-TGGTGTCGCCAGAACTACAAG-3’MT(°C): 65,1 Int. J. Med. Sci. 2011, 8 
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Reverse 
5’-GAAAGAGTCAATCCCATCTGTGT-3’MT(°C): 
63,1 
mFATP4 
Forward 
5’-GTGAGATGGCCTCAGCTATC-3’MT(°C): 61,4 
Reverse 
5’-GAAGAGGGTCCAGATGCTCT-3’MT(°C): 62,3 
hFATP4 
Forward 
5’-CGGTTCTGGGACGATTGTAT-3’MT(°C): 63,6 
Reverse 
5’-AACCTGGTGCTGGTTTTCTG-3’MT(°C): 64 
human ß-actin 
Forward 
5’-AGGATGCAGAAGGAGATCACT-3’MT(°C): 61,8 
Reverse 
5’-GGGTGTAACGCAACTAAGTCATAG-3’MT(°C): 
62,5 
Levels  of  the  following  thermal  profile  were 
used: Enzyme activation at 95° for 10min followed by 
35 amplification cycles of 15 sec at 95° (denaturation 
step), 30 sec at 60° (annealing step) and 30 sec at 72° 
for  Elongation.  Paying  attention  the  melting  curves 
show just one peak for every sample, data acquisition 
occurred at the elongation step of each cycle, and the 
threshold cycle (Ct) for each sample was calculated by 
determining the point at which fluorescence exceeded 
the threshold limit. 
For use as internal standards, control plasmids 
including each gene were diluted to 10^310^7 copies. 
RT qPCRs were carried out in 96 well reaction plates 
using  Power  SYBR®  Green  PCR  Master  Mix  from 
Applied Biosystems. Results were analyzed using the 
software  by  7500  Fast  Real-Time  PCR  System  from 
Applied Biosystems and finally given as the relative 
expression  to  the  housekeeping  gene  for  human 
ß-actin. Results were collected from at least two in-
dependent experiments using each time three differ-
ent RNA samples and  were presented as a ratio  to 
actin expression. 
Statistical analysis 
All  values  are  reported  as  mean  and  standard 
error of the mean (SEM). The ANOVA test was used 
to test for statistical significance. Probability values of 
p < 0.05 were set as threshold for statistical signifi-
cance. 
RESULTS 
Subcellular localisation of FATP2, FATP4, 
ACSL1 and CD36  
To study the role of FATP2, FATP4, ACSL1 and 
CD36 in LCFA transport of hepatoma cells we first 
investigated the localization of these proteins. So far 
the  localization  of  FATP2  was  described  in  peroxi-
somes  as  well  as  at  the  plasma  membrane  of  rat, 
mouse and monkey cells [27, 34, 45] and additionally 
in the endoplasmatic reticulum (ER) of COS cells [46]. 
FATP4  was  originally  reported  to  be  located  at  the 
plasma membrane and act there like a transporter for 
LCFA  [28].  However,  recent  studies  could  show  a 
localization in the ER of mouse small intestine, HeLa, 
Caco-2, Ptk2, MDCK, 3T3-L1 and COS cells [29, 47]. 
For localization studies HA-tagged FATP2 as well as 
GFP-tagged  FATP4  was  transiently  transfected  in 
HuH7 and HepG2 cells. In these cells they showed a 
similar  reticular  cellular  pattern  typifying  the  ER 
membranes (figure 1 and 2). ER localization was as-
sured  by  co-expression  with  the  ER-marker 
mRFP-Sec61ß.  FATP2  and  FATP4  did  neither 
co-localize  with  plasma  membrane 
(ssGFPglycTMDpcx)  nor  peroxisomal  (peroxiso-
mal-mRFP1) marker proteins.  
ACSL1 is one of the most extensively character-
ized  proteins  of  the  ACSL-family.  Nevertheless  its 
localization is still debatable [27, 29, 48, 49]. To specify 
the  localization  of  FLAG-tagged  ACSL1  we  did  a 
co-staining with the mitochondria-marker (mito-RFP) 
and found a co-localization in both HuH7 and HepG2 
cell lines (figure 3). No overlap was found with plas-
ma  membrane  (ssGFPglycTMDpcx),  peroxisomes 
(peroxisomal-mRFP1),  ER  (mRFP-Sec61ß)  or  lipid 
droplets (adipophilin-mRFP1), where it has been pre-
viously described to be located as well [27]. 
Figure 4 shows that CD36 could be co-localized 
with  PLAP,  a  marker  for  plasma  membrane.  The 
staining presented the complete size of the cell and 
typical branches on the cell surface. This localization 
is in line with previous results in COS cells [19]. No 
co-localization  with  mitochondria  (mito-RFP),  ER 
(mRFP-Sec61ß), lipid droplets (ADP-mRFP1) and pe-
roxisomes (peroxisomal-mRFP1) could be detected. 
Analysis of fatty acid uptake 
To  investigate  the  LCFA  uptake  in  HuH7  and 
HepG2 cells, we transiently expressed FATP2, FATP4, 
ACSL1 and  CD36  and  incubated  the  cells  with  dif-
ferent FA substrates. Transcription of FATP4, FATP2, 
ACSL1, and  CD36  was  measured  by  efficiency  cor-
rected real-time PCR relative to ß-actin to estimate the 
basal und overexpression rates. Transfection resulted 
in a several fold increase of mRNA expression: over-
expression was 271-fold (ACSL1), 6777-fold (FATP2), 
3165-fold (FATP4) and 181-fold (CD36) in HuH7 cells, 
respectively. To work with physiological fatty acids, 
we first used radio-labeled oleate in a 1:1 relation to 
BSA and incubated the cells for 60 sec with the mix. Int. J. Med. Sci. 2011, 8 
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All proteins significantly increased the oleate uptake 
in HuH7 (figure 5) as well as in HepG2 cells (data not 
shown)  in  comparison  to  GFP  overexpression.  GFP 
served as control and did not show any influence on 
LCFA uptake compared to non-transfected cells. 
We  also  confirmed  that  overexpression  of 
FATP2,  FATP4  and  ACSL1  leads  to  an  increased 
acyl-CoA-synthetase activity in HuH7 cells (figure 6) 
and HepG2 cells (data not shown), when using oleate 
as substrate. CD36 had no influence on the ACS ac-
tivity of the cells in comparison to the control. 
 
 
Figure 1. Localisation of FATP2 in HepG2 (A+C) and HuH7 (B) cells. The ER marker protein mRFP (red) was cotrans-
fected. For FATP2-HA we used mouse anti-HA antibody from Santa Cruz and Cy2 fluorescently-labelled secondary anti-
body. FATP2 shows a reticular cellular structure representing ER membranes. There was no match with plasmamembrane 
marker (ssGFPglyc) (B) or peroxisomal marker proteins (peroxisomal-RFP) (C) in both cell lines. Bar: 10 µm. Int. J. Med. Sci. 2011, 8 
 
http://www.medsci.org 
604 
 
Figure 2. Localisation of FATP4 in HuH7 cells. GFP-FATP4 flags the same reticular structures as the ER marker protein 
mRFP (A). There was no concordance with plasmamembrane (ssGFPglyc) and RFP-FATP4 (C) or peroxisomal marker 
proteins (peroxisomal-RFP) and GFP-FATP4 (B). Results are representative for HepG2 cells as well. Bar: 10 µm. 
 
 
To compare FA uptake to the expression level of 
the individual protein at a single cell level, we per-
formed FACS analysis as described [29]. FATP2, CD36 
and  ACSL1  were  transiently  overexpressed  and  in-
cubated  for  a  short  time  with  the  fluorescent  long 
chain  fatty  acid  B12.  FATP4  was  used  as 
RFP-construct,  FATP2,  CD36  and  ACSL1  were 
marked  by  immunofluorescence.  In  initial  experi-
ments our cells were analysed by a confocal micro-
scope  and  classified  by  visual  characteristics.  We 
could  register  an  increased  fluorescence  level  and 
thus  increased  B12  uptake  upon  overexpression  of 
FATP2,  FATP4  and  ACSL1  compared  to  their 
non-expressing counterparts. Surprisingly, there was 
no significant uptake detectable upon overexpression 
with CD36 (figure 7).  Int. J. Med. Sci. 2011, 8 
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Figure 3. Localisation of ACSL1 in HepG2 cells. For ACSL1-FLAG we used mouse anti-FLAG antibody (Sigma) and Cy2 or 
Cy3 fluorescently-labelled secondary antibodies. HepG2 cells were cotransfected with mito-RFP, a marker for mitochondria 
and a plasmamembrane marker protein (ssGFPglyc). There was an overlap with the mitochondria staining (mito-RFP) (A) 
and no concordance with plasmamembrane staining (ssGFPglyc) (B). In addition ACSL1 had no overlap with lipid droplets 
(adipophilin-mRFP1) (C) or peroxisome (peroxisomal-RFP) marker proteins (D). Results are representative for HuH7 cells 
as well. Bar: 10 µm. Int. J. Med. Sci. 2011, 8 
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Figure 4. GFP-CD36 transiently cotransfected with PLAP in HepG2 cells and clustered with mouse anti PLAP. CD36 flags 
typical branches on the cell surface compatible with the plasma membrane (A). There was no matching of CD36 staining with 
ER (mRFP) (B) or lipid droplet (adipophilin-mRFP1) marker proteins (C). Results are representative for HuH7 cells as well. 
Bar: 10 µm. Int. J. Med. Sci. 2011, 8 
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Figure 5. Oleate uptake of transient transfected HuH7 cells after 60 sec of incubation with oleate-BSA mix (in pmol ole-
ate/µg protein). Controls for endogenous oleate uptake were transfected with GFP plasmid. The proteinoverexpression 
resulted in a significant increase in the rate of [3H]oleate uptake within 60 sec (p<0.05). Values are means ± SD of three 
independent experiments. 
 
 
 
Figure 6. Acyl-CoA synthetase activity (in pmol oleoyl-CoA/minute/µg protein) determined from lysates of transiently 
transfectet HepG2 cells. Controls for endogenous ACS activity were transfected with GFP plasmid. Values are means ± SD 
of three independent experiments (p<0.05). Int. J. Med. Sci. 2011, 8 
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Figure  7.  HuH7  cells  with  short 
time  incubation  of  B12  fatty  acid. 
Overexpression  of  RFP-FATP4, 
FATP2-HA  and  ACSL1-FLAG  in-
creased  B12  uptake  into  the  cell. 
B12 was accumulated and stored in 
lipid droplets. CD36-FLAG did not 
show any enhanced uptake of B12 
compared to control cells. 
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To gain quantitative data a larger number of in-
dividual cells was analysed by FACS. The standard 
dot plot output of the FACS software confirmed that 
there is a higher B12 uptake with overexpression of 
FATP2, FATP4 and ACSL1, but not with CD36. Even 
though we could collect a large amount of cells with 
the  FACS  analysis,  we  could  not  correlate  the  B12 
uptake  with  the  level  of  expression  of  CD36  accu-
rately.  
To  correlate  individual  transfected  cells  with 
their special fluorescent intensity of B12-FA that has 
been taken up, data were transformed by a spread-
sheet method (figure 8) [42]. Each data point in figure 
8 contains all cells with the same fluorescence value of 
the transfected protein (equals the level of expression) 
and  the  average  B12-FA  fluorescence  of  these  cells 
(equals  the  amount  of  FA  taken  up).  Control  cells 
were transfected with mRFP and pcDNA and show 
the endogenous B12 uptake of HuH7 cells. The cal-
culated slopes (m) and the correlation coefficients (r) 
confirm a strong linear correlation between the level 
of protein expression of RFP-FATP4, FATP2-HA and 
ACSL1-FLAG and B12 uptake.  
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Figure 8. FACS analysis of fluorescent fatty acid uptake of transiently transfected HuH7 cells. Thespreadsheets correlated the level of 
expression with the amount of fluorescent fatty acid uptake (B12-FA). (A) HuH7 cells transfected with RFP-FATP4.Control cells were 
transfected with red fluorescent mRFP protein. RFP-FATP4 (r=0.73) enhanced fatty acid uptake depending on its relative level of ex-
pression in comparison to control cells only expressing mRFP (r=0.4). The low increase of the fatty acid uptake of control cells (r=0.4) 
could be explained by endogenous FATP4 expression in HuH7 cells. FATP2-HA (B) (r=0.92) and ACSL1-FLAG (C) (r=0.64) overex-
pressing cells enhanced the uptake of fatty acids as well. The overexpression of CD36-FLAG (D) (r=0.2) did not significantly correlate with 
the uptake of fatty acids. Control cells were transfected with pcDNA3 (E) (r=0.18). The pictured diagrams are representative for three 
independent experiments. Int. J. Med. Sci. 2011, 8 
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Figure 9. Bodipy fatty acid uptake of RFP-FATP4, CD36-FLAG, FATP2-HA and ACSL1-FLAG transfected HuH7 cells in 
arbitrary units based on FACS analyses. Bodipy fatty acid uptake was correlated to the protein expression level of trans-
fected protein on a snigle cell basis. The gated overexpressing cells (in % of all cells gated) were multiplied with the cor-
responding overall mean of the fluorescence signal derived from the Bodipy fatty acid (SBodipy). HuH7 Cells transfeced with 
pcDNA3 were used as control and as background range and were set as base level of the x-axis. Uptake was performed with 
B12 fatty acid in experiments with FATP4, FATP2, ACSL1 and CD36 (CD36 B12) or with B16 (CD36 B16). The pictured 
diagram is representative for three independent experiments. 
 
 
 
To find out, which one of the investigated pro-
teins causes the quantitative highest FA uptake, we 
compared Bodipy fatty acid uptake to the fluorescent 
level of the overexpressed candidate protein on a sin-
gle cell basis. The percentage of gated cells was mul-
tiplied with the mean of the fluorescence signal de-
rived from B12. Presenting this data in arbitrary units 
showes that FATP2 overexpressing cells seem to have 
the  quantitative  highest  uptake  of  fluorescent  fatty 
acid  compared  to  their  expression  levels  (figure  9). 
This means less FATP2 within one cell is necessary to 
incease FA uptake to a similar level compared to other 
candidate proteins. 
Again we could not find any increased uptake of 
B12-FA when HuH7 cells were transfected with CD36. 
In contrast to studies of Koonen et al. [50] even with 
another ligand (Bodipy-C16) there was no difference 
between  the  uptake  of  untransfected  cells  and  cells 
with CD36 overexpression (figure 9). This likely in-
dicates that Bodipy FAs – in opposite to [3H]oleate - 
are no ligands for CD36. 
DISCUSSION 
Translocation  of  long  chain  fatty  acids  at  the 
plasma membrane is achieved by a complex interplay 
of several co-existing mechanisms [1, 3]. Members of 
the FATP family have been previously proposed to be 
the long sought transport proteins that facilitate LCFA 
uptake at the plasma membrane. However, this is still 
a matter of debate [1-4, 6, 8]. Recent data suggest that 
at least FATP4 is an intracellular enzyme localized in 
the ER [29, 47]. In our studies we could localize FATP2 
and FATP4 only in the ER of HuH7 and HepG2 cells. 
This confirms other results which found FATP4 in the 
ER  of  mouse  small  intestine,  COS,  MDCK,  3T3-L1 
adipocytes  and  Vero  cells  [29].  In  accordance  to 
Steinberg et al. we could find FATP2 in the ER of he-
patoma cells [46]. Other studies located FATP2 at the 
plasma membrane of hepatocytes [34] or in fibroblast 
peroxisomes  promoting  FA  converting  via 
ß-oxidation [45]. We could not affirm these findings in 
our cell lines. The reason for this difference remains 
unclear, but it could be due to different methods of 
overexpression, materials and cells used for analysis. 
Consequently,  in  Huh7  as  well  as  in  HepG2  cells, 
FATP4  as  well  as  FATP2  are  no  transport  proteins 
directly  facilitating  LCFA  transport  at  the  plasma 
membrane. In fact, they are located intracellular and 
are involved in FA metabolism (probably production 
of  phospholipids  and  triglycerides)  upon  their 
acyl-CoA  activity.  They  more  likely  increase  LCFA 
uptake indirectly by metabolic trapping, which means Int. J. Med. Sci. 2011, 8 
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that long chain fatty acids are activated and then me-
tabolized.  A  decreased  intracellular  free  LCFA  con-
centration would drive more LCFAs into the cell [2, 8].  
Acyl-CoAs  are  involved  in  both  anabolic  and 
catabolic  pathways.  The  disturbance  of  these  path-
ways  is  linked  to  hepatic  steatosis,  hyperlipidemia 
and  insulin  resistance  [51].  Increased  LCFA  uptake 
could also be correlated to the ACSL1 activity [29] and 
accumulation of triglycerides could be shown upon 
overexpression in HepG2 cells [52]. Therefore we also 
analyzed the localization and effect of ACSL1 in our 
hepatoma cell models. In contrast to previous results 
on primary rat hepatocytes where ACSL1 was located 
in ER [49], we could point out its localization in mi-
tochondria of HuH7 and HepG2 cells. This would be 
in  line  with  their  potential  role  in  mice  adipocytes 
[53].  In  the  majority  of  cases  the  localization  in 
hepatocytes  has  been  studied  when  ACSL1  was 
overexpressed, therefore ER localization might also be 
a phenomenon of different levels of overexpression. 
Another explanation might be a different function of 
ACSL1 depending on the cell type or tissue.  
Our studies affirm, that FA uptake into hepato-
ma cells can be regulated by enzymes. Accordingly, 
we could identify an increased oleate uptake in addi-
tion to an elevated ACS activity for ACSL1, FATP2 
and FATP4 after overexpression. We believe that in-
creased enzyme activity could diminish the intracel-
lular  pool  of  free  LCFA  and  create  a  concentration 
gradient of free LCFA in the intra- and extracellular 
domain.  For  an  increased  LCFA  uptake  ACS  have 
therefore not to be localized at the plasma membrane 
as found in our results.  
As we could demonstrate an inceased [3H]oleate 
uptake upon FATP2, FATP4, ACSL1 and CD36 over-
expression compared to control cells, we have to lim-
itate, that expression levels by transient transfection 
are varying from cell to cell in these experiments. As 
the Bradford assay measures the total protein level of 
each sample, we could not draw conclusions to the 
amount  of  overexpressed  protein  reliably.  Accord-
ingly, these data as well as the data of ACS activity 
should not be considered quantitatively but qualita-
tively. 
For this reason we performed fatty acid uptake 
assays on a single cell level via FACS analyses and 
spreadsheet calculations. We could affirm that at least 
FATP2, FATP4 and ACSL1 have significant influence 
on the level of LCFA uptake depending on their ex-
pression levels. Therefore they can be important tar-
gets for the treatment of metabolic liver diseases as a 
dose dependent effect of inhibition seems likely. In-
terestingly, targeting FATP2 and FATP4 have already 
become more attractive as potent small molecule in-
hibitors have been identified [33, 54]. 
In our FACS analysis we could identify FATP2, 
the most expressed FATP in liver cells [30], to have the 
highest influence on LCFA uptake in correlation to its 
protein expression level in hepatoma cells. Therefore 
the  treatment  of  nonalcoholic  fatty  liver  disease 
(NAFLD)  or  NASH  by  inhibiting  the  uptake  of  FA 
into the liver cell could be theoretically influenced by 
blocking  especially  FATP2  function.  Interestingly, 
actual  data  show  that  liver  specific  inhibition  of 
FATP2  expression  in  vivo  resulted  in  a  reduced 
hepatosteatosis  with  improving  glucose  and  insulin 
levels  [34].  In  addition,  recent  results  from  an  high 
throughput  screen  on  HepG2  and  CaCo-2  cells 
demonstrate that FA transport can be inhibited in a 
FATP-specific  manner  without  causing  cellular  tox-
icity [33]. This makes FATP2 to a target of high inter-
est for further metabolic strategies. 
When  overexpressed  in  cultured  fibroblasts 
CD36 increases LCFA uptake  [55]. Moreover, CD36 
knockout mice show reduced uptake of oleate in iso-
lated adipocytes [56]. In HuH7 and HepG2 cells we 
could  increase  [3H]oleate  uptake  by  transient  over-
expression of CD36 significantly. In FACS analyses an 
enlarged  uptake  of  B12  FA  was  missed.  Even  with 
B16FA, previously been shown to be a CD36 ligand 
[50],  there  was  not  a  significant  gain  of  FA  uptake 
(figure  9).  The  differences  between  [3H]oleate  and 
Bodipy  fatty  acid  could  probably  be  explained  by 
special substrate specificities of CD36.  
We  could  show  that  CD36  is  located  in  the 
plasmamembrane  of  HuH7  and  HepG2  cells.  This 
strengthens  results  from  other  studies  that  locate 
CD36 in raft and non raft plasma membrane domains 
[19, 20] and suggests a significant role of CD36 in the 
uptake mechanism of FA in hepatoma cells. As CD36 
has no ACS activity, it possibly increases FA uptake 
by accumulating FA at the plasma membrane. Recent 
data show that CD36 is indeed increased in liver of 
morbidly  obese  patients  and  correlated  to  free  FA 
levels [22]. It has also been shown that downregula-
tion  of  CD36  can  prevent  steatohepatitis  in  hyper-
lipidemic mice [57]. This way CD36 is also a target for 
the treatment of NAFLD or NASH.  
In conclusion, we studied four different proteins 
that can promote FA uptake into hepatoma cells de-
pending  on  their  expression  levels.  An  attractive 
therapeutic candidate seems to be FATP2 as it had the 
strongest  influence  on  fatty  acid  uptake  in  our  ex-
periments. It is highly expressed in liver tissue and an 
effective selective inhibition with small molecules has 
already been shown [33]. It will be interesting to see, if Int. J. Med. Sci. 2011, 8 
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this concept could be really integrated into therapeu-
tic strategies. 
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